See more : Corline Biomedical AB (CLBIO.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Taro Pharmaceutical Industries Ltd. (TARO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Taro Pharmaceutical Industries Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Better World Acquisition Corp. (BWACW) Income Statement Analysis – Financial Results
- New China Life Insurance Company Ltd. (601336.SS) Income Statement Analysis – Financial Results
- FreeBit Co., Ltd. (3843.T) Income Statement Analysis – Financial Results
- China Oriental Group Company Limited (CUGCY) Income Statement Analysis – Financial Results
- Blue Blends (India) Limited (BLUEBLENDS.NS) Income Statement Analysis – Financial Results
Taro Pharmaceutical Industries Ltd. (TARO)
About Taro Pharmaceutical Industries Ltd.
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1950 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 629.18M | 572.95M | 561.35M | 548.97M | 644.77M | 669.89M | 661.91M | 879.39M | 950.75M | 862.94M | 759.29M | 670.95M | 543.08M | 392.54M | 357.64M | 329.04M | 319.55M | 252.27M | 297.74M | 284.13M | 315.46M | 211.58M | 150.13M | 103.80M | 83.79M | 66.70M | 61.00M | 56.50M | 49.60M | 42.10M | 28.50M | 26.50M | 20.60M | 13.30M | 11.80M | 9.20M | 8.80M |
| Cost of Revenue | 324.20M | 304.63M | 268.23M | 252.31M | 245.04M | 224.17M | 198.41M | 208.14M | 171.79M | 186.36M | 179.28M | 176.13M | 177.50M | 159.16M | 154.77M | 148.34M | 133.40M | 123.52M | 128.69M | 119.40M | 102.45M | 79.47M | 54.74M | 35.34M | 30.90M | 26.30M | 25.90M | 22.70M | 19.10M | 15.70M | 12.50M | 12.20M | 9.50M | 6.90M | 6.00M | 5.10M | 5.00M |
| Gross Profit | 304.98M | 268.32M | 293.12M | 296.66M | 399.73M | 445.72M | 463.51M | 671.25M | 778.97M | 676.59M | 580.01M | 494.83M | 365.59M | 233.38M | 202.87M | 180.69M | 186.16M | 128.75M | 169.05M | 164.73M | 213.00M | 132.11M | 95.40M | 68.46M | 52.88M | 40.40M | 35.10M | 33.80M | 30.50M | 26.40M | 16.00M | 14.30M | 11.10M | 6.40M | 5.80M | 4.10M | 3.80M |
| Gross Profit Ratio | 48.47% | 46.83% | 52.22% | 54.04% | 62.00% | 66.54% | 70.03% | 76.33% | 81.93% | 78.40% | 76.39% | 73.75% | 67.32% | 59.45% | 56.72% | 54.92% | 58.25% | 51.04% | 56.78% | 57.98% | 67.52% | 62.44% | 63.54% | 65.95% | 63.12% | 60.57% | 57.54% | 59.82% | 61.49% | 62.71% | 56.14% | 53.96% | 53.88% | 48.12% | 49.15% | 44.57% | 43.18% |
| Research & Development | 64.54M | 52.24M | 54.54M | 60.15M | 59.78M | 63.24M | 70.42M | 70.64M | 71.16M | 65.51M | 55.43M | 46.51M | 33.46M | 36.39M | 34.24M | 35.04M | 29.82M | 36.27M | 45.77M | 41.94M | 40.60M | 26.37M | 19.63M | 14.59M | 11.73M | 9.20M | 9.70M | 8.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 85.09M | 57.06M | 52.81M | 56.76M | 83.44M | 78.28M | 0.00 | 0.00 | 0.00 | 81.95M | 79.23M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 113.28M | 56.62M | 38.54M | 36.66M | 6.53M | 9.91M | 0.00 | 0.00 | 0.00 | 9.79M | 7.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 218.94M | 198.37M | 113.68M | 91.36M | 93.41M | 89.97M | 88.20M | 85.66M | 92.37M | 87.64M | 91.73M | 86.44M | 94.56M | 107.90M | 102.20M | 99.03M | 97.27M | 109.05M | 108.10M | 123.30M | 97.72M | 52.48M | 42.99M | 31.90M | 25.93M | 20.70M | 18.00M | 17.70M | 23.40M | 17.90M | 13.60M | 11.70M | 7.70M | 5.10M | 4.70M | 3.50M | 3.50M |
| Other Expenses | 64.54M | 2.46M | 4.23M | 2.89M | 3.02M | 1.81M | 1.89M | 11.21M | 2.68M | 2.74M | 1.37M | 3.35M | 784.00K | 2.62M | 3.36M | 2.82M | 0.00 | 27.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.41M | 4.10M | 3.30M | 2.40M | 1.80M | 1.40M | 1.00M | 700.00K | 500.00K | 400.00K | 600.00K | 300.00K | 0.00 |
| Operating Expenses | 283.47M | 250.61M | 168.22M | 151.51M | 153.19M | 153.21M | 158.61M | 156.30M | 163.53M | 153.15M | 147.16M | 132.95M | 128.02M | 144.30M | 136.45M | 134.07M | 127.09M | 145.32M | 153.87M | 165.24M | 138.32M | 78.85M | 62.62M | 46.50M | 42.07M | 34.00M | 31.00M | 29.00M | 25.20M | 19.30M | 14.60M | 12.40M | 8.20M | 5.50M | 5.30M | 3.80M | 3.50M |
| Cost & Expenses | 607.67M | 555.24M | 436.44M | 403.82M | 398.23M | 377.38M | 357.02M | 364.44M | 335.31M | 339.51M | 326.44M | 309.07M | 305.51M | 303.45M | 291.22M | 282.41M | 260.49M | 268.84M | 282.56M | 284.65M | 240.77M | 158.32M | 117.36M | 81.83M | 72.98M | 60.30M | 56.90M | 51.70M | 44.30M | 35.00M | 27.10M | 24.60M | 17.70M | 12.40M | 11.30M | 8.90M | 8.50M |
| Interest Income | 56.19M | 22.10M | 8.19M | 20.17M | 33.65M | 33.54M | 19.93M | 14.47M | 12.60M | 9.68M | 6.68M | 4.03M | 0.00 | 985.00K | 0.00 | 0.00 | 1.16M | 2.23M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 1.25M | 1.65M | 1.36M | 725.00K | 256.00K | 304.00K | 131.00K | 473.00K | 928.00K | 1.52M | 2.51M | 0.00 | 5.25M | 16.53M | 795.00K | 23.98M | 11.45M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 31.09M | 34.94M | 25.92M | 23.68M | 6.55M | 18.60M | 16.50M | 14.83M | 14.85M | 15.80M | 16.57M | 17.77M | 18.62M | 18.83M | 18.45M | 21.19M | 22.61M | 25.11M | 25.28M | 19.62M | 14.42M | 8.40M | 6.76M | 5.99M | 4.41M | 4.10M | 3.30M | 2.40M | 1.80M | 1.40M | 1.00M | 700.00K | 500.00K | 400.00K | 600.00K | 300.00K | 0.00 |
| EBITDA | 38.40M | 52.65M | 164.89M | -413.78M | 305.31M | 282.13M | 303.01M | 509.61M | 624.19M | 493.40M | 444.88M | 328.58M | 249.64M | 108.89M | 84.87M | 67.81M | 82.84M | -17.32M | 40.47M | 18.90M | 74.69M | 61.58M | 39.26M | 27.37M | 15.13M | 10.40M | 7.20M | 7.10M | 7.10M | 8.50M | 2.00M | 2.60M | 3.70M | 1.70M | 1.00M | 500.00K | 300.00K |
| EBITDA Ratio | 8.36% | 9.19% | 37.46% | 132.63% | 39.25% | 42.11% | 53.74% | 57.95% | 65.65% | 57.18% | 58.59% | 61.19% | 45.97% | 27.74% | 23.73% | 20.61% | 25.92% | -6.86% | 13.59% | 6.65% | 27.93% | 29.11% | 26.15% | 26.37% | 18.05% | 15.59% | 11.80% | 12.57% | 14.31% | 20.19% | 7.02% | 9.81% | 17.96% | 12.78% | 8.47% | 5.43% | 3.41% |
| Operating Income | 21.51M | 17.71M | 184.37M | 704.44M | 246.54M | 296.19M | 303.01M | 514.95M | 614.47M | 527.63M | 430.25M | 328.58M | 236.79M | 86.47M | 63.06M | 43.80M | 59.06M | -70.35M | 15.19M | -516.00K | 74.69M | 53.26M | 32.78M | 16.10M | 10.81M | 6.40M | 4.10M | 4.80M | 5.30M | 7.10M | 1.40M | 1.90M | 2.90M | 900.00K | 500.00K | 300.00K | 300.00K |
| Operating Income Ratio | 3.42% | 3.09% | 32.84% | 128.32% | 38.24% | 44.21% | 45.78% | 58.56% | 64.63% | 61.14% | 56.67% | 48.97% | 43.60% | 22.03% | 17.63% | 13.31% | 18.48% | -27.89% | 5.10% | -0.18% | 23.68% | 25.17% | 21.83% | 15.51% | 12.90% | 9.60% | 6.72% | 8.50% | 10.69% | 16.86% | 4.91% | 7.17% | 14.08% | 6.77% | 4.24% | 3.26% | 3.41% |
| Total Other Income/Expenses | 75.36M | 20.50M | -47.06M | -536.22M | 51.50M | 60.66M | -10.64M | 45.85M | 22.35M | 58.25M | 13.65M | 7.28M | 4.15M | -11.09M | -15.97M | 259.00K | -18.52M | -11.45M | -7.89M | -6.42M | -1.73M | -298.00K | -2.40M | -3.53M | -3.80M | -2.70M | -2.10M | -1.50M | -1.80M | -1.20M | -400.00K | -800.00K | -1.40M | -400.00K | 100.00K | 100.00K | 100.00K |
| Income Before Tax | 82.67M | 38.21M | 77.86M | -391.07M | 298.04M | 356.85M | 292.37M | 560.80M | 636.82M | 581.68M | 443.91M | 335.86M | 240.93M | 75.38M | 47.09M | 44.06M | 40.55M | -81.81M | 7.29M | -6.93M | 72.96M | 52.96M | 30.37M | 12.57M | 7.01M | 3.70M | 2.00M | 3.30M | 3.50M | 5.90M | 1.00M | 1.10M | 1.50M | 500.00K | 600.00K | 400.00K | 400.00K |
| Income Before Tax Ratio | 13.14% | 6.67% | 13.87% | -71.24% | 46.22% | 53.27% | 44.17% | 63.77% | 66.98% | 67.41% | 58.46% | 50.06% | 44.36% | 19.20% | 13.17% | 13.39% | 12.69% | -32.43% | 2.45% | -2.44% | 23.13% | 25.03% | 20.23% | 12.11% | 8.37% | 5.55% | 3.28% | 5.84% | 7.06% | 14.01% | 3.51% | 4.15% | 7.28% | 3.76% | 5.08% | 4.35% | 4.55% |
| Income Tax Expense | 28.80M | 12.77M | 19.59M | 9.67M | 53.49M | 74.73M | 81.95M | 103.78M | 95.31M | 96.06M | 82.73M | 67.80M | 35.97M | 10.48M | -69.66M | 13.54M | 6.21M | 872.00K | 1.62M | -16.99M | 11.48M | 8.41M | 4.38M | 2.54M | 1.47M | 1.40M | 600.00K | 1.10M | 1.50M | 2.50M | 800.00K | 700.00K | 700.00K | 1.10M | 700.00K | 200.00K | 400.00K |
| Net Income | 53.87M | 25.45M | 58.27M | -400.74M | 244.24M | 281.78M | 211.15M | 456.36M | 540.93M | 484.26M | 360.39M | 266.21M | 204.27M | 64.08M | 114.02M | 30.52M | 34.34M | -82.68M | 5.68M | 11.08M | 61.16M | 44.56M | 25.99M | 10.03M | 5.54M | 2.30M | 1.40M | 2.20M | 2.00M | 3.40M | 200.00K | 900.00K | 800.00K | -200.00K | -200.00K | 100.00K | 0.00 |
| Net Income Ratio | 8.56% | 4.44% | 10.38% | -73.00% | 37.88% | 42.06% | 31.90% | 51.89% | 56.90% | 56.12% | 47.46% | 39.68% | 37.61% | 16.32% | 31.88% | 9.28% | 10.74% | -32.77% | 1.91% | 3.90% | 19.39% | 21.06% | 17.31% | 9.66% | 6.61% | 3.45% | 2.30% | 3.89% | 4.03% | 8.08% | 0.70% | 3.40% | 3.88% | -1.50% | -1.69% | 1.09% | 0.00% |
| EPS | 1.43 | 0.68 | 1.55 | -10.49 | 6.35 | 7.23 | 5.26 | 11.05 | 12.62 | 11.31 | 8.14 | 5.96 | 1.06 | 1.59 | 2.91 | 0.78 | 0.99 | -2.82 | 0.19 | 0.38 | 2.12 | 1.55 | 1.11 | 0.47 | 0.28 | 0.12 | 0.07 | 0.11 | 0.10 | 0.18 | 0.01 | 0.05 | 0.06 | -0.02 | -0.02 | 0.01 | 0.00 |
| EPS Diluted | 1.43 | 0.68 | 1.55 | -10.49 | 6.35 | 7.23 | 5.26 | 11.05 | 12.62 | 11.31 | 8.14 | 5.95 | 1.06 | 1.53 | 2.81 | 0.76 | 0.98 | -2.82 | 0.19 | 0.37 | 2.06 | 1.52 | 0.99 | 0.42 | 0.26 | 0.12 | 0.07 | 0.11 | 0.10 | 0.17 | 0.01 | 0.05 | 0.06 | -0.02 | -0.02 | 0.01 | 0.00 |
| Weighted Avg Shares Out | 37.58M | 37.58M | 37.64M | 38.21M | 38.46M | 38.99M | 40.16M | 41.30M | 42.83M | 42.83M | 44.28M | 44.68M | 44.68M | 40.27M | 39.23M | 39.20M | 34.73M | 29.35M | 29.25M | 29.14M | 28.85M | 28.75M | 23.42M | 21.42M | 20.15M | 20.00M | 20.00M | 20.00M | 20.00M | 19.43M | 20.00M | 18.00M | 14.55M | 13.33M | 13.33M | 10.00M | 11.81M |
| Weighted Avg Shares Out (Dil) | 37.58M | 37.58M | 37.64M | 38.21M | 38.46M | 38.99M | 40.16M | 41.30M | 42.83M | 42.83M | 44.28M | 44.72M | 44.72M | 41.85M | 40.57M | 40.42M | 35.22M | 29.35M | 29.59M | 29.93M | 29.69M | 29.31M | 26.26M | 23.86M | 21.52M | 20.00M | 20.00M | 20.95M | 21.05M | 20.00M | 20.00M | 18.00M | 14.55M | 13.33M | 13.33M | 10.00M | 11.81M |
FINAL REMINDER TARO DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Taro Pharmaceutical Industries Ltd. Investors to Participate in the Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. ("Taro" or "the Company") (NYSE:TARO)...
FINAL TARO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Taro Pharmaceutical Industries Ltd. Investors to Join the Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. ("Taro" or "the Company") (NYSE:TARO)...
TARO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Taro Pharmaceutical Industries Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, Nov. 10, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. (“Taro” or “the Company”)...
TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Taro Pharmaceutical Industries Ltd. to Contact the Firm Today!
NEW YORK, NY / ACCESSWIRE / November 10, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. ("Taro" or "the Company") (NYSE:TARO)...
TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Taro Pharmaceutical Industries Ltd. to Contact the Firm Today!
NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. ("Taro" or "the Company") (NYSE:TARO)...
TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Taro Pharmaceutical Industries Ltd. to Contact the Firm Today!
NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. ("Taro" or "the Company") (NYSE:TARO)...
TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. ("Taro" or "the Company") (NYSE:TARO)...
TARO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Shareholders Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. ("Taro" or "the Company") (NYSE:TARO)...
TARO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Taro Pharmaceutical Industries Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. (“Taro” or “the Company”)...
TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Stockholders Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. ("Taro" or "the Company") (NYSE:TARO)...
Source: https://incomestatements.info
Category: Stock Reports